FDA Clears Newest Version of Respiratory Motion’s ExSpiron

Respiratory Motion’s most recent version of its Exspiron minute ventilation monitoring system received FDA approval, clearing it for use in hospital and ancillary medical settings.

The system aims to improve the care and hospital experience of adults who are receiving opioids and/or sedatives and adults at increased risk of respiratory risks, such as congestive heart failure or sleep apnea.

A clinical study reported in December 2017 laid the groundwork for the agency’s approval of the system’s use in children one year of age or older, and the company is now working to extend approval to newborns and premature infants.